Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on September 9, 2005
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyi147
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
35/9/536    most recent
hyi147v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sakamoto, J.
Right arrow Articles by Yasutomi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sakamoto, J.
Right arrow Articles by Yasutomi, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Foundation for Promotion of Cancer Research
Received April 4, 2005
Accepted July 26, 2005

Original Article

An Individual Patient Data Meta-Analysis of Adjuvant Therapy with Carmofur in Patients with Curatively Resected Colon Cancer

Junichi Sakamoto 1*, Chikuma Hamada 1, Mahbubur Rahman 1, Susumu Kodaira 1, Katsuki Ito 1, Hiroaki Nakazato 1, Yasuo Ohashi 1, and Masayuki Yasutomi 1

1 Meta-Analysis Project, Japanese Society for Cancer of the Colon and Rectum, Secretariat, Department of Epidemiological and Clinical Research Information Management, Kyoto University, Graduate School of Medicine, Kyoto, Japan

* To whom correspondence should be addressed.
Junichi Sakamoto, E-mail: sakamoto{at}pbh.med.kyoto-u.ac.jp


  Abstract

Background: Oral carmofur, either as a single or in combination with other chemotherapeutic agents, has been used as adjuvant chemotherapy for curatively resected colon cancer patients. Past trials and meta-analyses indicate that it is somewhat effective in extending survival of patients with this cancer. The objective of this study was to perform a reappraisal of randomized clinical trials conducted in this regard.

Methods: We designed an individual patient-based meta-analysis of relevant clinical trials to examine the benefit of oral carmofur for curatively resected colon cancer in terms of overall survival (OS) and disease-free survival (DFS).

Results: We analyzed individual patient data of three randomized clinical trials, which met the predetermined inclusion criteria. These three trials had a combined total of 2152 patients, carmofur as adjuvant chemotherapy compared with surgery-alone, 5 years follow-up, intention-to-treat-based analytic strategy and similar end points (OS and DFS). In a pooled analysis, 5 year OS rates were 80.4 and 76.4%, and 5 year DFS rates 76.9 and 71.0%, respectively, in carmofur and surgery-alone group. Oral carmofur had significant advantage over surgery-alone in terms of both OS [pooled hazard ratio, 0.82; 95% confidence interval (CI) = 0.68-0.99; P = 0.043] and DFS (pooled hazard ratio, 0.77; 95% CI = 0.65-0.91; P = 0.003).

Conclusions: This individual patient-based meta-analysis demonstrated that oral carmofur significantly improves both OS and DFS in patients with curatively resected colon cancers.

Keywords: colorectal cancer; carmofur; chemotherapy; disease-free survival; overall survival; randomized clinical trials.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.